Loading stock…

Zymeworks Inc. (ZYME) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Zymeworks Inc.

ZYMEMarket cap $1.88BPrice $26.5

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Designs multifunctional antibody therapeutics that attack cancer cells in ways single-target drugs can't. Its bispecific antibody platform has landed licensing deals with pharma giants like Merck and BeiGene, turning lab science into royalty checks.

In Bastion Portfolios?

52W Return+44%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-36%1

Revenue Forecast

Rev CAGR (1y)+175%10

Rev CAGR (3y)+42%10

Rev CAGR (5y)+34%10

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+27%8

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-419%1

Net Income Margin-404%1

Free Cash Flow Margin-325%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-72%1

ROA-37%1

Earnings Stability44

GEAR+WEAK23

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)118

P/E Ratio (Forward 3y)na–

P/BV23.41

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd175

Yield

Free Cash Flow Yield-6.4%1

Dividend Yieldna–

Momentum

Short term

1 month return-6%5

3 month return-0%6

YTD return+1%5

Mid term

Price vs 52wHigh85%7

1 year return+59%9

Long term

3 year return+315%10

5 year return+8%4

Risk Shield

Price Risk

Beta1.04

Volatility52%3

Free Cash Flow

Free Cash Flow Margin-325%1

Free Cash Flow Yield-6.4%1

Quality

ROCE-43%1

Earnings Stability44

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

ZYMEZymeworks

Revenue FY25$106M

GROWTH RATING↗

STRONG84 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-36%1

Revenue, next 1Y+175%10

Revenue, next 3Y, CAGR+42%10

Revenue, next 5Y, CAGR+34%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+27%8

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 84% of companies worldwide.

Revenue is set to grow 42%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 42%/yr from here.

The runway holds up: revenue is set to grow 34%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 36%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%5

3-month return-0%6

YTD return+1%5

MID & LONG-TERM▾SCORE

% of 52-week high85%7

1-year return+59%9

3-year return+315%10

5-year return+8%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +315% over three years and +7.9% over five, ahead of 60% of the market.

It's up 59% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

WATCH

Returns sit at the market level over the past month (-6%), over three months (+0%) and so far this year (+1%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Zymeworks Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ZYMEZymeworks

Revenue FY25$106M

GROWTH RATING↗

STRONG84 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-36%1

Revenue, next 1Y+175%10

Revenue, next 3Y, CAGR+42%10

Revenue, next 5Y, CAGR+34%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+27%8

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 84% of companies worldwide.

Revenue is set to grow 42%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 42%/yr from here.

The runway holds up: revenue is set to grow 34%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 36%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%5

3-month return-0%6

YTD return+1%5

MID & LONG-TERM▾SCORE

% of 52-week high85%7

1-year return+59%9

3-year return+315%10

5-year return+8%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +315% over three years and +7.9% over five, ahead of 60% of the market.

It's up 59% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

WATCH

Returns sit at the market level over the past month (-6%), over three months (+0%) and so far this year (+1%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Zymeworks Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community